STADA Acquires GSK's Consumer Healthcare Portfolio to Expand its OTC Business
Shots:
- STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton- for venous treatment- Coldrex cold remedy- Cetebe vitamin C supplements- Mebucaine sore throat range and Tavegyl allergy brand
- The acquisition will strengthen STADA’s OTC portfolio and accelerates its growth in European countries. The transaction is expected to be completed in Q2’2020
- The acquisition follows STADA’s acquisition of GSK’s five OTC skincare brands-Ceridal- Eurax- Oilatum- Polytar- Savlon and pediatric cough remedies- Tixylix in EU and selected markets in the Asia-Pacific and Latin America regions
Click here to read full press release/ article
Ref: STADA | Image: GSK
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com